UK LEADER IN BREAKTHROUGH CANNABIS-BASED MEDICINES

Improving quality of life for patients

WHAT WE DO

GROW | EXTRACT | SELL

Licenced 100,000 sq ft
UK facility with indoor grow
and API extraction (EU-GMP)

CLINICAL TRIALS

UK’s only MHRA (conditionally) approved chronic pain trial using cannabis-based
medicines

BREAKTHROUGH R&D

IP generation and developing
pipeline of prescription
medicines

OUR MISSION

Celadon’s mission is to improve quality of life for patients most in need by developing
breakthrough cannabis-based medicines

Celadon was founded in 2018 after cannabis-based medicinal products (CBMPs) were legalised in the UK, and the company went public on the AIM market of the London Stock Exchange in 2022.

Everything at Celadon starts with improving patients’ quality of life. Cannabis-based medicines have shown rapid growth internationally, with a growing evidence base for its role in treating a variety of conditions (e.g. epilepsy, multiple sclerosis, autism). Celadon’s primary focus is chronic pain – a large, unaddressed market (8 million adults in the UK, 50 million in the US, 100 million in Europe), with many problems with existing opioid treatments.

Celadon is uniquely positioned as a vertically integrated pharmaceutical company to deliver its patient-first mission.  

The company has raised over £20 million to develop its licenced EU-GMP 100,000 sq ft UK facility  to grow high-THC cannabis and extract to API for its medicines.

It has developed its MHRA conditionally approved chronic pain trial that has the potential to create a robust data set to support reimbursement on the National Health Service in the UK.

Celadon’s in-house R&D programme is focused on novel IP generation and its partnership with biopharma Kingdom Therapeutics is developing a licenced cannabinoid drug for Autism Spectrum Disorder. 

OUR JOURNEY

In a market with significant regulatory and capital barriers to entry, Celadon is building the UK’s leading pharmaceutical cannabinoid company. 

2018

Celadon founded after medical cannabis legalisation in UK.

2019-20

Celadon applies to UK regulators and MHRA, helping create the UK’s regulatory framework for cultivation and production.

2021

Celadon successfully granted licence by UK regulators for legal cultivation of test batches of high THC cannabis.

2021

Phase 1 of construction is completed at Celadon’s 100,000 sq ft UK facility, and first harvest is completed.

2021

Acquisition of majority shareholding in LVL Health , which has the only MHRA conditionally approved chronic pain trial using cannabis based medicines.

2021

Acquisition of minority stake in Kingdom Therapeutics, a UK leading biopharma developing a licensed cannabinoid treatment for autism spectrum disorder.

2022

IPO on the AIM market of the London stock exchange, bringing Celadon’s total raise to £20m. Celadon is the only company since GW Pharma to be admitted to the exchange.

2022
Phase 2 construction begins, which will take Celadon’s cultivation capacity to around 3 tonnes once complete.

2022
Celadon completes in 7th harvest in the summer of 2022, to support its MHRA application for EU-GMP for its high-THC cannabinoid API.

2022

LVL’s chronic pain trial enrols its first patients, with early results very promising for the reduction of pain (and opioid usage) and increasing sleep.

2023

Celadon receives its GMP registration from the MHRA, following a successful site inspection.

2023

Celadon granted updated licence by UK regulators allowing the commercial sale of its cannabis product.

BUILDING ON STRONG FOUNDATIONS

Visit our Investor Centre to learn more about the company, view our results and see the latest news.

Share Price
98 p
£64 M

MARKET CAP

12,321

VOLUME

100.00

DAY HIGH

95.13

DAY LOW

WORKING WITH REGULATORS

Celadon is one of the first companies to receive EU-GMP approval by MHRA, and licenced by UK regulators to cultivate test batches of medicinal cannabis.

Celadon is one of a small number of companies globally to be awarded EU-GMP certification to manufacture high-THC cannabinoid active pharmaceutical ingredients (API); GMP allows Celadon to produce API for pharmaceutical prescription drugs and sell its product to the market.

Celadon’s chronic pain clinical trial (through LVL) has been conditionally approved by the UK’s MHRA. In contrast to observational studies, this Government-approved trial aims to provide a robust data set to support re-imbursement on the National Health Service.


Warning: Cannot modify header information - headers already sent by (output started at /home/customer/www/celadonpharma.com/public_html/wp-config.php:1) in /home/customer/www/celadonpharma.com/public_html/wp-content/plugins/ays-popup-box/public/class-ays-pb-public.php on line 137

 

ENVIRONMENT

Celadon uses a highly controlled indoor cultivation environment in order to produce plants to the tightest pharmaceutical tolerances and cannabinoid content. Hydroponics is used to grow plants in a soilless substrate, with mineral salts dissolved into high quality filtered water and delivered direct to the roots of the plant. Micro-zoned sensors monitor every aspect of the environment in real time; from the room’s temperature, lighting cycles and humidity, to the plant’s mineral absorption and transpiration rates. This allows Celadon to build a data bank of optimal growing conditions for each strain, as well as adjust the room automatically.

TRACKING

Celadon has a bespoke “track and trace” system throughout the production process, providing complete transparency. Each plant is given a unique QR code, allowing it to be traced from its origins through to the final product. IOT boxes are used to automatically feed data into the system, from environmental data to the product’s weight, at each stage of production. This provides full visibility over the production process, as well as inventory tracking and accurate cost analysis which feeds into our accounting systems.

This will close in 0 seconds

Medical Cannabis Market, Transparency Market Research May 2022

This will close in 0 seconds

Stannard et al, (2016) Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable

This will close in 0 seconds

Stannard et al, (2016) Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable

This will close in 0 seconds

Stannard et al, (2016) Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable

This will close in 0 seconds

 

ENVIRONMENT

Celadon uses a highly controlled indoor cultivation environment in order to produce plants to the tightest pharmaceutical tolerances and cannabinoid content. Hydroponics is used to grow plants in a soilless substrate, with mineral salts dissolved into high quality filtered water and delivered direct to the roots of the plant. Micro-zoned sensors monitor every aspect of the environment in real time; from the room’s temperature, lighting cycles and humidity, to the plant’s mineral absorption and transpiration rates. This allows Celadon to build a data bank of optimal growing conditions for each strain, as well as adjust the room automatically.

TRACKING

Celadon has a bespoke “track and trace” system throughout the production process, providing complete transparency. Each plant is given a unique QR code, allowing it to be traced from its origins through to the final product. IOT boxes are used to automatically feed data into the system, from environmental data to the product’s weight, at each stage of production. This provides full visibility over the production process, as well as inventory tracking and accurate cost analysis which feeds into our accounting systems.

This will close in 0 seconds

Legalised in 2018

This will close in 0 seconds

Legalised in 37 States Limited Federal legalisation

This will close in 0 seconds

Legalised in 2016

This will close in 0 seconds

Legalised in 2016

This will close in 0 seconds

Legalised in 2016 Rapid growth to >200k patients (2019-21)

This will close in 0 seconds

Legalised in 2001

This will close in 0 seconds

BUSINESS DESCRIPTION

 

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism.

Its 100,000 sq. ft UK facility operates to an EU-GMP standard and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. The Company's subsidiary, LVL, owns a MHRA conditionally-approved clinical trial using cannabis based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics which is developing a licenced cannabinoid medicine to treat children with Autism Spectrum Disorder.

This will close in 0 seconds

COUNTRY OF INCORPORATION/OPERATION

 

Celadon Pharmaceuticals Plc is incorporated in England and Wales and is listed solely on the London Stock
Exchange Alternative Investment Market (AIM), and is subject to the UK City Code on Takeovers and Mergers.

TIDM: CEL.L
ISIN: GB00BDQYGP38

There are no restrictions on the transfer of Celadon Pharmaceutical’s shares.

This will close in 0 seconds

AIM SECURITIES IN ISSUE

 

The following information is correct as at 29th September 2023.

The Company’s issued share capital comprises

61,669,773 ordinary shares

Each with a nominal value of 1 pence

So far as the Company is aware, 44.47% of its issued share capital is not in public hands.

This will close in 0 seconds